drugset / Trial / NCT02118064
Phase II Study to Evaluate G17DT in Combination With Irinotecan in Patients With Colorectal Carcinoma
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This study was designed to evaluate the ability for G17DT to slow or arrest tumor growth in patients with refractory colon cancer who had been previously treated with an Irinotecan-based chemotherapy.
Timeline
- Start
- 2001-03
- Primary completion
- 2002-12
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | G17DT Immunogen | Vaccine | 500 ug | Intramuscular |
| Background | Irinotecan | Small molecule | 125 mg/m2 | Intravenous |